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Ganoderma lucidum was characterized in terms of nutritional value and chemical composition. There-
after, ethanolic Soxhlet extracts were evaluated for antioxidant, anti-inﬂammatory, antityrosinase,
antimicrobial and cytotoxic effects, and further characterized in terms of phenolic acids, polysaccharides
and triterpenoids. Finally, the obtained extracts were tested as cosmeceutical ingredients. G. lucidum
proved to be a source of macronutrients and important bioactive compounds such as terpenoids,
specially triterpenoids, and polysaccharides. In the extracts, ganoderic acids C2, A and H were the most
abundant triterpenic acids and protocatechuic, p-hydroxibenzoic and syringic acids the identiﬁed phe-
nolics. The developed cosmeceutical formulation preserved the extract bioactivities, presented a light-
yellow colour and a pH of 4.6, which is considered appropriate for cosmeceutical's design. Behind the
important nutritional/bioactive composition of G. lucidum, a potential towards its valorisation in the ﬁeld
of cosmeceuticals is foreseeable, as deduced from the bioactivities of its ethanolic extract and preser-
vation in the tested formulation.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Ganoderma lucidum (Curtis) P. Karst. is a medicinal mushroom
with interesting chemical composition imparting nutraceutical
properties and pharmacological beneﬁts either as immune sup-
pressors, hypocholesterolemic agents or as coadjutant treatments
in diseases such as cancer, hypertension, insomnia, anorexia,
dizziness and chronic hepatitis, among others (Zhao et al., 2016).
Currently, G. lucidum is one of the most sought after medicinal
mushrooms in oriental countries, being popularly known as Lingzhi
in China, Reishi in Japan and Yeongji in South Korea (Baby et al.,
2015; Bishop et al., 2015; Grienke et al., 2015). This species is rich
in several bioactive compounds mainly polysaccharides, terpe-
noids, nucleotides, steroids, fatty acids, proteins, and glycopeptides,
being the polysaccharidic and triterpenic components the most
reported ones (Liu et al., 2016b).
The polysaccharide composition of G. lucidum (GLP) includesseveral monomers (glucose, mannose, galactose, fucose, xylose,
rhamnose and arabinose) that are described to contribute signiﬁ-
cantly to its immunomodulatory, antioxidant, antitumour and
antibacterial properties (Ferreira et al., 2015; Liu et al., 2016a).
Among the terpenes, the triterpenes (ganoderic acids, ganoderenic
acids, ganoderols and lucideric acids) are the most abundant ones,
having been reported to be responsible for its antitumour, anti-
inﬂammatory, antioxidant, anti-hepatitis, antimalarial, hypoglyce-
mic, antimicrobial and anti-HIV-1 properties (Baby et al., 2015;
Bishop et al., 2015; Grienke et al., 2015; Van Nguyen et al., 2015).
The phenolic composition of G. lucidum has also been widely
studied and phenolic acids represent the most prominent class
including chlorogenic, cinnamic, gallic, protocatechuic, p-hydrox-
ybenzoic and p-coumaric acids. These molecules have been iden-
tiﬁed as contributors to its antioxidant, antimicrobial,
antityrosinase and anti-inﬂammatory properties (Heleno et al.,
2013, 2012; Min-Young et al., 2008; Sheikh et al., 2014; Stojkovic
et al., 2014). Besides all these bioactive compounds, G. lucidum
nutritional composition reveals high potential to be used in the
design of dietary supplements (e.g., tablets and capsules) for oral
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The use of G. lucidum bioactive extracts in the design of cos-
meceutical formulations for topical application is receiving special
attention. It is supported by existing reports on their power as
tyrosinase inhibitors, inﬂammatory mediator suppressors and as
photoprotective agents, which makes them multifunctional in-
gredients that can be used to control hyperpigmentation, sup-
pressing skin inﬂammatory diseases and preventing skin photo-
aging (Taoﬁq et al., 2016a, 2016c; Wu et al., 2016). Because of the
above mentioned interesting properties, several mushroom ex-
tracts and their bioactive components are either presently used or
patented to be used as cosmetics ingredients (Wu et al., 2016).
There are also studies on the stability and rheological properties of
several vehicles added with these bioactive ingredients for appli-
cation in cosmetic, nutraceutical and pharmaceutical industries (Li
et al., 2013b; Liu et al., 2016).
Herein, the fruiting bodies of G. lucidum were studied: i) in
terms of nutritional and chemical composition to highlight its po-
tential to be consumed as functional foods; ii) as a source of
bioactive compounds, namely, triterpenic and phenolic acids which
show antioxidant, anti-inﬂammatory, antityrosinase, antitumour
and antimicrobial activities, for cosmeceutical purposes. This last
concept was studied by incorporating G. lucidum ethanolic extracts
in a cosmetic base cream, which was further characterized in terms
of physico-chemical and bioactive parameters.
2. Materials and methods
2.1. Standards and reagents
Acetonitrile (99.9%), n-hexane (95%) and ethyl acetate (99.8%)
were of HPLC grade from Fisher Scientiﬁc (Lisbon, Portugal). Fatty
acids methyl ester (FAME) reference standard mixture 37 (standard
47885-U) were purchased from Sigma (St. Louis, MO, USA), as well
as phenol, starch, ursolic acid, ganoderic acid A, alpha and delta
tocopherols, sugar standards and p-iodonitrotetrazolium chloride
(INT). Phenolic standards were obtained from Extrasynthese
(Genay, France). Tocol and beta and gamma tocopherols (50 mg/
mL) were purchased from Matreya (Pleasant Gap, PA, USA). 2,2-
Diphenyl-1-picrylhydrazyl (DPPH) was obtained from Alfa Aesar
(Ward Hill, MA, USA). Dulbecco's modiﬁed Eagle's minimum
essential medium (DMEM), fetal bovine serum (FBS), penicillin,
streptomycin, Griess reagent system (Promega), DMSO, sulphor-
odamine B (SRB), lipopolysaccharide (LPS), 3,4-dihydroxy-L-
phenylalanine (L-DOPA), and mushroom tyrosinase enzyme were
obtained from Sigma-Aldrich Co. (Saint Louis, MO, USA). The cul-
ture media Muller Hinton broth (MHB) and Tryptic Soy Broth (TSB)
were obtained from Biomerieux (Marcy l’Etoile, France), as also,
blood agar with 7% sheep blood and Mac Conkey agar plates.
Perchloric acid 70%, glacial acetic acid and sulphuric acid were
purchased from Fischer chemicals (Loughborough, UK). Vanillin
was purchased from Labkem (Barcelona, Spain), ursolic acid was
purchased from Acros Organics (New Jersey, USA) while all other
chemicals and solvents were of analytical grade and purchased
from common suppliers. Water was treated in a Milli-Q water pu-
riﬁcation system (TGI Pure Water Systems, Greenville, SC, USA).
2.2. Ganoderma lucidum samples
The fruiting bodies of Ganoderma lucidum were provided by
Bioreishi - Agricultura Biologica, Lda, Portugal (Reishi producers;
Batalha, Portugal) as dry material. The specimens were reduced to
powder (20 mesh) and mixed to obtain homogeneous samples. For
all the experiments three independent samples were analysed and
all the assays were carried out in triplicate. The results areexpressed as mean values ± standard deviation (SD).
2.3. Nutritional properties and chemical composition of G. lucidum
fruiting bodies
Proximate composition. The proteins, fat, carbohydrates and ash
were determined using standard AOAC procedures (AOAC
International, 2016). The sample crude protein content (N  4.38)
was estimated by the Kjeldahl method; the crude fat was deter-
mined using a Soxhlet apparatus by extracting a known weight of
sample with petroleum ether; the ash content was determined by
incineration at 600 ± 15 C. The total carbohydrate was calculated
by difference and the energy content estimated using the following
equation: Energy (kcal) ¼ 4 (g protein) þ 4 (g carbohydrate) þ 9 (g
fat).
Sodium chloride content. The salt concentration in G. lucidumwas
determined according toMohr's Method, similarly to the procedure
described by Osaili et al. (2014), with slight modiﬁcations. Brieﬂy,
the sample (1 g) was suspended in distilled water (20 mL) and
ﬁltered. The procedure was repeated at least 5-fold and the pH
adjusted to z8.5 with sulfuric acid or sodium hydroxide, as
requested. Potassium chromate solution (5%, 1 mL) was then added
and the mixture titrated against AgNO3 (0.05 mol/L) until the ﬁrst
reddish colour (precipitate) appears. The salt concentration was
then calculated using the equation: Salt content % ¼ [(V titrated of
AgNO3  0.00292)]/[(m sample)]  100 and expressed as g/100 g
dry weight (dw).
Free sugars composition. Free sugars were identiﬁed and quan-
tiﬁed using high performance liquid chromatography with refrac-
tive index detection (HPLC-RI) (Fernandes et al., 2016). The
equipment integrates a pump (Knauer, Smartline system 1000,
Berlin, Germany), a degasser system (Smartline manager 5000), an
autosampler (AS-2057 Jasco) and an RI detector (Knauer Smartline
2300) and a column oven operating at 30 C (7971 R Grace oven).
The chromatographic separation was achieved with a Eurospher
100-5 NH2 column (5 mm, 4.6 mm  250 mm, Knauer). Quantiﬁ-
cation was conducted by the internal standard method (IS, rafﬁ-
nose), and using calibration curves obtained from commercial
standards. The results were recorded and processed using Clarity
2.4 software (DataApex, Prague, Czech Republic). Sugar contents
were expressed in g per 100 g of dw.
Fatty acids composition. Samples (1.5 g) were extracted using a
Soxhlet apparatus with petroleum ether as solvent. The samples
undergo transesteriﬁcation according to the procedure previously
reported by Fernandes et al. (2016). Analysis was carried out using
gas chromatography (DANI 1000, Contone, Switzerland), equipped
with a split/splitless injector and a ﬂame ionization detector (FID at
260 C). Separation was achieved with a Macherey-Nagel (Duren,
Germany) column (50% cyanopropyl-methyl- 50% phenyl-
methylpolysiloxane, 30 m  0.32 mm ID  0.25 mm df). Fatty acids
identiﬁcation was made by comparison with relative retention
times of FAME peaks of standard samples. The results were recor-
ded and processed using CSW 1.7 software (DataApex 1.7, Prague,
Czech Republic), and expressed in relative percentage (%).
Tocopherols composition. Tocopherols were determined by HPLC
with ﬂuorescence detection (FP-2020; Jasco, Easton, MD, USA) us-
ing excitation at 290 nm and emission at 330 nm (Fernandes et al.,
2016). The chromatographic separation was achieved with a Poly-
amide II (5 mm, 250 mm  4.6 mm) normal-phase column from
YMC Waters (Dinslaken, Germany) operating at 30 C. Quantiﬁca-
tion was based on calibration curves obtained from commercial
standards using the IS (tocol) methodology. The results were
expressed in mg per 100 g of dw.
Total polysaccharides. Total polysaccharides were determined
according to Vazirian et al. (2014) with some modiﬁcations. Brieﬂy,
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and further ﬁltered under vacuum; this step was repeated twice.
The ﬁltrated extract was lyophilized and the polysaccharide frac-
tion dissolved in water at a concentration of 5 mg/mL. This solution
(1 mL) was mixed with phenol (4%, 25 mL) followed by sulphuric
acid (1 mL). The sample solutions were then stirred for 30s and
their absorbance measured at 548 nm against a blank (distilled
water), using a UVevisible-light spectrophotometer (UV-160A;
Shimadzu Corporation, Kyoto, Japan). Starch (5e50 mg/mL) was
used as a standard and the results were expressed as mg of starch
equivalents per g of dw.
Total terpenoids. Total terpenoids were determined according to
the procedure described by Ghorai et al. (2012). Dry sample
(800 mg) was extracted with methanol (10 mL) for 1 h and sub-
sequently ﬁltered. Afterwards, the supernatant (1 mL) was mixed
with chloroform (0.4 mL) and sulphuric acid (0.6 mL). The sample
absorbance was measured at 538 nm against a blank (methanol
added with the other reagents), using a UVevisible-light spectro-
photometer (UV-160A; Shimadzu Corporation, Kyoto, Japan).
Linalool (0.1875e6mg/mL inmethanol) was used as a standard and
results were expressed in mg of linalool equivalents per g of dw.
Total triterpenes. The triterpenes' content was evaluated ac-
cording to the protocol described by Chang et al. (2012). Shortly,
G. lucidum extract (10 mg) was dissolved in methanol (1 mL), af-
terwards an aliquot (100 mL) of this solution was mixed with
vanillin-glacial acetic acid solution (150 mL, 5% w/v) and perchloric
acid solution (500 mL, 70%). Then the sample solutions were heated
at 60 C for 45 min and let to cool in an ice-water bath followed by
the addition of glacial acetic acid (2.25 mL). Subsequently, absor-
bance was measured at 548 nm against a blank (methanol with
other reagents), using a UVevisible-light spectrophotometer (UV-
160A; Shimadzu Corporation, Kyoto, Japan). Ursolic acid
(0.0078e0.5 mg/mL in methanol) was used as standard. Results
were expressed as mg ursolic acid equivalents per g of dw.
2.4. G. lucidum ethanolic extracts and characterization
Extraction procedure. The dried powder of G. lucidum (3 g) was
extracted in a Soxhlet apparatus for 5e6 h (35 ± 5 min per cycle)
using ethanol. Finally, the solvent was evaporated under reduced
pressure (rotary evaporator Büchi R-210, Flawil, Switzerland) to
obtain the dried ethanolic extracts.
Individual triterpenes and phenolic compounds composition. For
the individual phenolic and triterpenoid compounds characteriza-
tion, the obtained extracts were dissolved in ethanol (5.5 mg/mL),
ﬁltered through a 0.22 mm nylon syringe ﬁlter and analyzed by
HPLC-DAD-ESI/MSn in a Dionex Ultimate 3000 UPLC system
(ThermoScientiﬁc, San Jose, CA, USA). The equipment consisted of a
diode array detector coupled to an electrospray ionization mass
detector, a quaternary pump, an auto-sampler (kept at 5 C), a
degasser and an automated thermostated column section (kept at
35 C). Waters Spherisorb S3 ODS-2 C18 (3 mm, 4.6  150 mm,
Waters, Milford, MA, USA) column was used. The solvents used
were (A) 0.1% formic acid inwater and (B) acetonitrile. The gradient
elution applied was: 15% B (0e5 min), 15% B to 20% B (5e10 min),
20e25% B (10e20 min), 25e35% B (20e30 min), 35e50% B
(30e40 min), the column was then re-equilibrated, using a ﬂow
rate of 0.5 mL/min. Data was collected simultaneously with DAD
(280 nm) and in negative mode detection on a Linear Ion Trap LTQ
XL mass spectrometer (ThermoScientiﬁc, San Jose, CA, USA),
following a procedure previously described by Bessada et al. (2016).
Xcalibur® data system (ThermoScientiﬁc, San Jose, CA, USA) was
used in data acquisition. For identiﬁcation, retention times, UVeVIS
and mass spectra were compared with available standards; when
not available data from literature was used to tentatively identifythe remaining compounds. Quantiﬁcation was based on calibration
curves of available phenolic and triterpenoid standards constructed
based on the UV signal. Compounds with unavailable commercial
standards were quantiﬁed using the calibration curve of the most
similar available standard. The results were expressed as mg/g of
extract.
Antioxidant activity. The antioxidant activity was evaluated by
DPPH radical-scavenging activity and reducing power (Taoﬁq et al.,
2016b). The extract concentrations providing 50% of antioxidant
activity or 0.5 of absorbance (EC50) were calculated from the graphs
of antioxidant activity percentages for DPPH or absorbance at
690 nm for reducing power assay, against extract concentrations.
Trolox was used as positive control.
Antityrosinase activity: Tyrosinase inhibition assay was per-
formed using L-DOPA as substrate according to the procedure
described by Taoﬁq et al. (2016b). The ethanolic extract was dis-
solved in 50% DMSO at 10 mg/mL. Assays were carried out in a 96-
well microplate with each well containing 40 mL of the sample,
80 mL of phosphate buffer (0.1 M, pH 6.8), 40 mL of tyrosinase
enzyme (60 units/mL) and 40 mL of L-DOPA (3.5 mM). The per-
centage of tyrosinase inhibition was calculated as follows:
[(Acontrol  Asample)/Acontrol]  100. EC50 values were calcu-
lated from the calibration curve of tyrosinase inhibition percentage
versus extract concentration.
Anti-inﬂammatory activity. The LPS-induced NO production by
Murine macrophage (RAW 264.7) cell lines was determined as ni-
trite concentration in the culture medium according to the method
previously described by Taoﬁq et al. (2016b). Dexamethasone
(50 mM)was used as a positive control. Themousemacrophage-like
cell line RAW 264.7 stimulated with LPS was used in the assay.
Nitric oxide (NO) production was studied with Griess Reagent
System kit. Results were expressed as EC50 values (mg/mL) equal to
the sample concentration providing a 50% inhibition of NO pro-
duction. Dexamethasone was used as positive control.
Cytotoxicity in human tumour cell lines. The cytotoxicity was
determined using four human tumour cell lines, HeLa (cervical
carcinoma), HepG2 (hepatocellular carcinoma), MCF-7 (breast
adenocarcinoma) and NCI-H460 (non-small cell lung cancer),
following a procedure already descried by the authors Souza et al.
(2015). The cell growth inhibition was measured using the sulfo-
rhodamine B assay, were the number of pigmented cells is directly
proportional to the total protein mass and therefore to the number
of bounded cells. The results were expressed in GI50 values; sample
concentration that inhibited 50% of the net cell growth and ellip-
ticine was used as positive control.
Cytotoxicity in non-tumour liver cells primary culture. A freshly
harvested porcine liver, obtained from a local slaughter house, was
used in order to obtain the cell culture, designated as PLP2. The
growth inhibition was evaluated using the SRB assay, as previously
described by Abreu et al. (2011). The results were expressed in GI50
values; sample concentration that inhibited 50% of the net cell
growth and ellipticine was used as positive control.
Antimicrobial activity. The tested bacterial strains were clinical
isolates obtained from patients hospitalized in various departments
at the Hospital Center of Tras-os-Montes and Alto Douro (Vila Real,
Portugal). Four Gram-positive bacteria (Enterococcus faecalis, iso-
lated from urine; Listeria monocytogenes, methicillin-resistant
Staphylococcus aureus (MRSA), isolated from expectoration;
methicillin-sensitive S. aureus (MSSA), isolated from wound
exudate), six Gram-negative bacteria (Escherichia coli, E. coli ESBL,
Klebsiella pneumoniae, K. Pneumoniae ESBL; Morganella morganii,
and Proteus mirabilis, all isolated from urine; Pseudomonas aerugi-
nosa, isolated from expectoration). The yeast, Candida albicans
(isolated from urine) was also tested. Microorganism's identiﬁca-
tion and susceptibility tests were performed by the microdilution
Table 1
Nutritional and chemical composition of G. lucidum fruiting bodies.
Component Mean ± SD
Nutritional value (g/100 g)
Lipids 2.50 ± 0.02
Proteins 6.72 ± 0.04
Ash 2.4 ± 0.2
Available carbohydrates 38.0 ± 0.7
Total carbohydrates 88.4 ± 0.2
Energy (kcal/100 g) 201 ± 3
NaCl 0.42 ± 0.02
Free sugars (g/100 g)
Fructose 2.15 ± 0.04
Tocopherols (mg/100 g)
alpha-Tocopherol 18.1 ± 0.2
delta-Tocopherol 123 ± 7
Fatty acids (%)*
C16:0 21.3 ± 0.3
C18:0 5.8 ± 0.2
C18:1n9 12.7 ± 0.1
C18:2n6 42.4 ± 0.1
SFA (%) 39.3 ± 0.4
MUFA (%) 14.3 ± 0.1
PUFA (%) 46.4 ± 0.3
Total content of biomolecules
Polysaccharides (mg starch/g) 15.4 ± 0.2
Terpenoids (mg linalool/g) 27.2 ± 0.7
Triterpenoids (mg ursolic acid/g) 5.6 ± 0.5
Values are expressed in dry weight basis. *17 more fatty acids were identiﬁed
(data not shown) but with relative percentages lower than 3%. SFA- Saturated
Fatty Acids; MUFA- Monounsaturated Fatty Acids; PUFA- Polyunsaturated
Fatty Acids. Palmitic acid (C16:0); stearic acid (C18:0); oleic acid (C18:1n-9);
linoleic acid (C18:2n6).
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The microorganisms were cultivated and the determination of
the minimal inhibitory concentration (MIC) was performed on a
96-well microplate by the method p-iodonitrotetrazolium chloride
(INT) colorimetric assay antimicrobial activity was evaluated ac-
cording to (Taoﬁq et al., 2016b). The ethanolic extract was dissolved
in 25% DMSO at 50 mg/mL. Initially, 100 mL of the extract solution
was added to 380 mL of culture medium; afterwards, 20 mL of
inoculum (1.5  108 CFU/mL) was added thus achieving a concen-
tration range of 10 to 0.156 mg/mL. The plates were then incubated
at 37 C, for 24 h, in an oven (Jouan, Berlin, Germany) and the MIC
concentrations were determined after adding INT (0.2 mg/mL) and
after incubation at 37 C for 30 min. Viable microorganisms
reduced the yellow dye to a pink color. MIC was deﬁned as the
lowest extract concentration that prevented this change, thus
showing complete inhibition of bacterial growth.
2.5. Development of cosmeceutical formulations based on
G. lucidum ethanolic extracts
Incorporation of the extracts in a base cream. A cosmetic cream
with a light colour, free of fragrances, colorants, parabens, mineral
oils, sodium lauryl sulphate (SLS), propylene glycol, and ethoxylates
purchased from Fagron Iberica S.A.U. (Barcelona, Spain) was used.
According to the technical data available, this formulation has been
certiﬁed to be safe by the US Food and Drug Administration (FDA),
Regulation (EC) No 1907/2006dREACH and the National Health
Surveillance Agency (ANVISA) of Brazil. The incorporation was
achieved according to Taoﬁq et al. (2016b).
In order to cover all the bioactive properties evaluated, the base
creams were incorporated with 5 times the EC50 and MIC values
obtained for the extract which corresponds to a scale of 50 mg of
extract per gram of base cream. The formulation was continuously
mixed until sample homogenisation is fully achieved. The samples
were stored at 4 C till chemical characterization, evaluation of
bioactivity and determination of physicochemical properties.
Colour and pH measurements. The colour and pH measurements
were performed according to Caleja et al. (2017). The colour of each
cosmeceutical formulation was measured using a colorimeter
(model CR-400, Konica Minolta Sensing Inc., Tokyo, Japan). Mea-
surements were sampled in three different points, and the average
considered the true colour value. Colour space values were regis-
tered using the data software “Spectra Magic Nx” (version CM-
S100W 2.03.0006). The pH measurement was performed, in trip-
licate, directly in the cream with a HI 99161 pH-meter (Hanna In-
struments, Woonsocket, Rhode Island, USA).
Bioactive properties. The cosmeceutical formulations were dis-
solved in an aqueous solution of 50% DMSO at 50 mg/mL for anti-
oxidant activity evaluation; in 50% DMSO at 50 mg/mL for
antityrosinase activity and in 5% DMSO at 100 mg/mL for antimi-
crobial activity evaluation (following the procedures described
previously). The cosmeceutical formulations were extracted with
methanol (20 mL) for 30 min, ﬁltered, dried in a rotary evaporator,
and re-dissolved in ethanol:water (20:80 v/v) for phenolic acids
and triterpenes' analysis.
3. Results and discussion
3.1. Nutritional and chemical properties of G. lucidum fruiting
bodies
The results for thenutritional composition ofGanoderma lucidum
are presented in Table 1. Carbohydrates were the most abundant
compounds, followed by proteins, fat, ash and salt. The results are
fairly consistent with the ones reported by Stojkovic et al. (2014)even though the origin of the samples was different (Serbia).
Regarding the free sugars, fructose was the only one identiﬁed in
G. lucidum. Regarding the fatty acids (Table 1), polyunsaturated fatty
acids (PUFA) were the most abundant ones due to the high contri-
bution of linoleic acid followed by saturated fatty acids (SFA) and
monounsaturated fatty acids (MUFA). These results suggest G. luci-
dum as an important dietary source of PUFAs, which have been re-
ported as effective agents in the support of the general body well-
being by preventing several chronic diseases (Wang et al., 2012).
Concerning the tocopherols, the alpha and delta isoforms were
found in G. lucidum, being d-tocopherol the most abundant one
(Table 1). This molecule has received special attention due to its
reported health promoting beneﬁts and potent antioxidant prop-
erties, being highly used in clinical dermatology, as photoprotection
skin agents against UV radiation (Thiele and Ekanayake-
Mudiyanselage, 2007). A very common trend in the pharmaceu-
tical and cosmetic industries involve the use of nutritional supple-
ments to manage health conditions; including a popular term used
among dermatologist and cosmetic formulators is “beauty pills”,
which involve the use of compounds such as vitamins, lycopene,
retinol, essential fatty acids and other compounds with antioxidant
properties to improve skin appearance (Draelos, 2010).
G. lucidum is therefore considered a complete “package” of
healthy food, being an excellent source of nutritional components,
as well as, of other non-nutritional compounds. When orally
ingested it is able to improve body function and wellbeing. Total
polysaccharides, terpenoids and triterpenoids were determined
(Table 1), being terpenoids the most abundant ones, followed by
polysaccharides and triterpenoids. The polysaccharide content is
partially in accordance with the one reported for strains of G.
lucidum sourced in Poland (about 18.45 mg glucose equiv/g dw)
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content reported in the present work was consistent with the one
recently described by Liu et al. (2017), where the triterpene amount
of G. lucidum was about 5.90 mg ursolic acid equiv/g dw.
Commercially, there are already available some nutraceutical
products containing G. lucidum extract, either alone or in combi-
nation with other mushroom species. Some of them include
Organic Rare Red Reishi™ (100% G. lucidum); Organic ReiShi-Gen
(50% G. lucidum and 50% Lentinula edodes); Organic Trimyco-
Gen™ (33% Cordyceps sinensis 33% G. lucidum 33% L. Edodes). These
products formulated in capsules, rich in triterpenes and b-glucans,
have been recently reported by Rathore et al. (2017) to protect the
body against oxidative stress and support the immune system. In
conclusion, formulating nutraceuticals from G. lucidum have shown
to present interesting health promoting beneﬁts.
3.2. G. lucidum ethanolic extracts as relevant bioactive extracts
The ethanolic extracts of G. lucidum were analysed by HPLC-
DAD-ESI/MS and the obtained proﬁles included phenolic acids
and triterpenic acids. Data regarding retention time, maximum
wavelengths, molecular ion and main fragment ions observed in
MS2, compounds identiﬁcation and individual quantiﬁcation are
presented in Table 2. A total of three phenolic acids (peaks 1e3),
identiﬁed by comparing their UV spectra, retention time and MS
fragmentation pattern with the ones of commercial standards,
were found in the G. lucidum extract, with p-hydroxybenzoic acid
being the most abundant. Concerning published data, proto-
catechuic and p-hydroxybenzoic acids are the most widely re-
ported phenolic acids in G. lucidum. Nevertheless, Yildiz et al.
(2015) have also detected the presence of syringic acid in the
methanolic extracts from this matrix, which is consistent with re-
sults achieved in this work. Heleno et al. (2012) and Stojkovic et al.
(2014) also reported the presence of p-coumaric and cinnamic acids
in the fruiting body of G. lucidum, but differences in the extraction
procedure, and used environment for mushroom maturation can
justify the dissimilarity found in the achieved phenolic composition
and other secondary metabolites proﬁles.
A total of 26 triterpenoids (peaks 4e7, 9e27 and 29e31) were
identiﬁed (Table 2), being four of them identiﬁed as ganoderic acid
derivatives and other two as unknown compounds (peaks 8 and
28). Thus, these unknown compounds could possibly be related
with triterpenoid acids presence. In fact, an ESI-MS spectrum in
negative mode was used in the present study and all triterpenoids
gave [M - H]- and [2M - H]- ions in their negative ion mass spectra.
The triterpenoids identiﬁed in the present work resulted from a
comparison with literature data, regarding the UV spectra, reten-
tion time and MS fragmentation pattern, namely with the one re-
ported for triterpenoids in the works of Guo et al. (2012); Liu et al.
(2014); Pecic et al. (2015); Qi et al. (2012)&Yang et al. (2007), which
also studied G. lucidum samples. Ganoderic acid H, followed by
ganoderic acid C2 and ganoderic acid A were the most abundant
triterpenoids acids present. Yang et al. (2007) and Hadda et al.
(2015) reported the presence of ganoderenic acid K in chloroform
extracts of G. lucidum from China and Algeria, suggesting that the
triterpenoids proﬁle depends on the extraction method employed
(namely used solvent) and the geographical origin of the strain.
However, most studies have reported a good repeatability in the
triterpenoids proﬁle of G. lucidum (Hadda et al., 2015; Hennicke
et al., 2016; Yang et al., 2007).
The results regarding the bioactivity of G. lucidum extracts are
presented in Table 3. The antioxidant results obtained are very
similar to the ones reported by Heleno et al. (2012) for DPPH radical
scavenging and reducing power, even though the authors per-
formed a different extraction procedure (maceration inmethanol:water mixture (80:20, v/v)). These authors also con-
ducted studies concerning phenolic and polysaccharidic extracts of
G. lucidum, being the antioxidant activity slightly lower in the latter,
suggesting that phenolic compounds play a more prominent role in
the free radical scavenging activity.
G. lucidum ethanolic extract also revealed tyrosinase inhibition
activity. To the authors best knowledge only Chien et al. (2008)
have reported the tyrosinase inhibition activity for ethanolic
extract of G. lucidum from Taiwan with a reported EC50 reaching
0.32 mg/mL, lower than the one obtained herein, possibly justiﬁed
by the used slightly different procedures. Kim et al. (2016) were
able to identify a bioactive compound, ganodermanondiol, which
suppressed the expression of tyrosinase-related protein (TRP-1,
TRP-2) and microphthalmia-associated transcription factor (MITF)
thereby inhibiting the synthesis of melanin. Tyrosinase inhibitors
have shown to be effective ingredients towards skin lightening, and
among the bioactive compounds found in mushrooms, phenolics
have been reported as the ones that contribute most signiﬁcantly to
their antityrosinase activity (Taoﬁq et al., 2016a). Therefore, the
ethanolic extract studied in the present work can be further
exploited as a tyrosinase inhibitor to reduce the severity of hy-
perpigmentation and decrease melanin biosynthesis, partly due to
the registered amount on phenolic acids. Regarding the anti-
inﬂammatory activity, aqueous, methanolic and ethanolic extracts
of G. lucidum presented activity mainly by inhibiting NO, PGE2,
TNF-a IL1-b production (Taoﬁq et al., 2016c). In the present study,
ethanolic extract of G. lucidum revealed anti-inﬂammatory activity
by inhibiting NO production. Even though the phenolic compounds
of mushrooms have been identiﬁed as the most important con-
tributors to their anti-inﬂammatory activity (Taoﬁq et al., 2015),
triterpenic acids such as ganoderic acid C1 and lanostane in G.
lucidum, have also contributed signiﬁcantly to its anti-
inﬂammatory activity (Taoﬁq et al., 2016c).
The numerous secondary metabolites contained in this mush-
room have attracted huge interest and one of the most complete
reported studies is the one on its cytotoxic effect (Amen et al., 2016;
Li et al., 2013b). In the present work, no toxicity was observed in
non-tumour porcine liver cells (PLP2) at the maximum tested
concentration (400 mg/mL). However, the extract was able to inhibit
all human tumour cell lines evaluated; with breast carcinoma cells
showing to be themost susceptible cells, followed by non-small cell
lung, hepatocellular and cervical carcinoma cells. Our results
against cervical carcinoma cells were mostly in line with the ones
reported by Cilerdzic et al. (2014) with a growth inhibitory effect of
61.17 ± 0.75 mg/mL, even though mushroom origin (Serbia) and
applied extraction procedure (maceration) were different. The re-
sults also correlated well with the statements reported by Reis et al.
(2015) for methanolic extract, namely a similar trend on the
registered activity was observed (MCF-7 > NCI-H460). Overall, a lot
of studies have been able to identify the titerpenes as the most
prominent class of compounds contributing to the shown cytotoxic
effect (Amen et al., 2016; Chen et al., 2016; Li et al., 2013a). The
mechanism of antitumour effect of this mushroom has been asso-
ciated with inducing autophagy (Reis et al., 2015), leading to
apoptosis, inhibition of tumour invasion and metastasis (Patel and
Goyal, 2012).
Finally, among the analysed bacterial strains, G. lucidum extract
showed the highest antibacterial activity against MSSA and MRSA
with corresponding lowest minimum inhibitory concentrations
(Table 3). Regarding the Gram-positive bacteria strains, Listeria
monocytogenes was the least inhibited followed by Enteroccocus
faecalis. For Gram negative bacteria, the extract was not able to
inhibit the growth of Morganella morganii and Pseudomonas aeru-
ginosa even at the highest tested concentration, while the two E.
coli and the two Klebsiella strains were inhibited. In brief, the
Table 2
Identiﬁcation and quantiﬁcation of triterpenes and phenolic acids in G. lucidum ethanolic extract.
Peak Rt
(min)
UV lmax
(nm)
[M-H]- and
[2M-H]-
(m/z)
MS2 and MS3
(m/z)
Tentative identiﬁcation Quantiﬁcation
(mg/g)
Phenolic acids
1 5.23 259,293sh 153 109(100) Protocatequic acid 1.807 ± 0.001
2 8.39 257 137 93(100) p-Hydroxybenzoic acid 2.98 ± 0.01
3 11.51 280 197 121(100) Syringic acid 1.51 ± 0.01
Total phenolic acid 6.30 ± 0.01
Triterpenes
4 29.06 259 533/1067 515(5),497(12),404(100),303(12) 3,7,15-Trihydroxy-4-
(hydroxymethyl)-11,23-dioxo-lanost-8-en-26-oic acid
14.21 ± 0.02
5 30.8 256 533/1067 515(5),497(21),453(16),423(11),319(5),303(8) 12-Hydroxyganoderic acid C2 4.51 ± 0.06
6 31.27 252 529/1059 511(10),467(100),449(11),434(5),431(15),419(8),312(8),285(5),263(11) 20-hydroxy-ganoderic acid AM1 11.40 ± 0.01
7 31.73 251 529/1059 511(13),499(100),481(6),465(18),438(28),419(18),367(11),287(11) 12-deacetylganoderic acid H 6.1 ± 0.1
8 32.28 255 547/1095 529(50),511(41),485(3),467(100),449(24),431(26),304(11),265(7) Ganoderic acid derivative 7.3 ± 0.13
9 33.94 258 531/1063 513(13),451(3),401(100),385(5),304(19),301(45),286(3),249(27) Ganoderic acid ɳ 25.41 ± 0.04
10 34.48 254 511/1023 493(23),449(100),431(5),413(15),405(3) Ganoderic acid F 17.97 ± 0.02
11 35.37 265 529/1059 511(5),467(100),449(20),437(29),317(10),301(5),263(5) 12-hydroxyganoderic acid D 6.86 ± 0.07
12 35.95 251 515/1031 497(100),453(31),437(8),303(19),287(5),235(3) Ganoderic acid derivative 21.20 ± 0.08
13 36.84 256 517/1035 499(100) 481(48),456(17),438(52),407(8),304(6),287(35) Ganoderic acid C2 38.7 ± 0.2
14 37.51 257 529/1059 511(5),481(7),467(100),451(14),438(38),424(3),319(5),303(3),301(5) Ganoderic acid C6 29.10 ± 0.08
15 38.16 256 529/1059 511(58),493(5),449(10),399(100),301(3) Ganoderic acid derivative 12.77 ± 0.01
16 38.46 256 531/1063 513(11),498(15),469(100),454(29),452(24),437(6),304(5),302(6),290(20),266(7) Ganoderic acid G 16.84 ± 0.07
17 38.75 248 513/1027 495(10),480(16),451(100),437(14),433(22),407(17),331(5),315(3),303(5),287(5) Ganoderenic acid B 10.66 ± 0.09
18 39.01 259 527/1055 509(26),465(6),397(100),355(4) Elfvingic acid derivative 10.41 ± 0.09
19 39.35 254 515/1031 497(10),453(100),439(5),409(5),304(21),287(12),263(3),250(14) Ganoderic acid B 23.99 ± 0.09
20 39.46 250 513/1027 495(100),479(27),462(12),451(30),433(31),381(25),301(15) Ganoderic acid derivative 22.4 ± 0.1
21 39.66 261 513/1027 495(21),480(5),451(100),433(24),381(6),301(6),247(3) Ganoderic acid AM1 15.82 ± 0.01
22 40.29 254 515/1031 497(100),480(5),454(6),436(10),302(8),301(4),285(3) Ganoderic acid A 36.77 ± 0.04
23 40.66 261 571/1143 553(100),511(8),481(3),468(8),437(3),423(2) Ganoderic acid H 41.1 ± 0.4
24 40.87 252 527/1055 509(20),479(13),465(100),435(3),421(3),317(3),301(3) Elfvingic acid A 9.83 ± 0.01
25 41.34 254 529/1059 511(10),496(22),493(21),467(100),449(61),434(4),319(6),317(8),301(16),300(11),299(12) Ganoderic acid derivative 11.56 ± 0.04
26 41.93 246 511/1023 493(12),478(20),449(100),435(15),431(4),405(4),329(3),301(4),285(5),283(3),261(4) Ganoderenic acid D 10.27 ± 0.07
27 42.55 255 513/1027 495(16),451(100),437(6),433(3),407(4),301(23),286(3),284(11),247(8) Ganoderic acid D 11.31 ± 0.01
28 42.74 245 509/1019 491(100),476(18),461(34),447(15),429(3),417(3),300(5),299(4) Ganoderic acid derivative 12.81 ± 0.08
29 43.15 256 511/1023 493(100),449(65),435(3),300(5),247(4) Ganoderic acid E 10.81 ± 0.07
30 43.95 255 569/1139 551(100),509(35),508(21),466(8) 12-acetoxyganoderic acid F 12.08 ± 0.07
31 44.92 272 513/1027 451(100),437(8),433(3),422(3),301(5) Ganoderic acid J 2.92 ± 0.05
Total triterpenoids 455 ± 1
Calibration curves used: 1-protocatechuic acid (y ¼ 214168x þ 27102; R2 ¼ 0.999); 2- p-hydroxybenzoic acid (y ¼ 208604x þ 173056; R2 ¼ 0.999); 3- syringic acid (y ¼ 376056x þ 141329; R2 ¼ 0.999); 4- ganoderic acid A
(y ¼ 2539.7x þ 16193; R2 ¼ 0.999).
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Table 3
Bioactive properties of G. lucidum ethanolic extract.
G.lucidum
ethanolic extract
Antioxidant activity (EC50 values, mg/mL)
DPPH scavenging activity 0.73 ± 0.01
Reducing power 0.15 ± 0.01
Cytotoxic activity (GI50 values, mg/mL)
MCF-7 (breast carcinoma) 61 ± 4
NCI-H460 (non-small cell lung carcinoma) 64 ± 3
HeLa (cervical carcinoma) 73 ± 3
HepG2 (hepatocellular carcinoma) 68.44 ± 0.08
PLP2 (non-tumour primary liver porcine cells) >400
Anti-inﬂammatory activity (EC50, mg/mL)
NO Inhibition 112 ± 1
Antityrosinase activity (EC50 values, mg/mL)
L-DOPA assay 2.81 ± 0.01
Antimicrobial activity (MIC, mg/mL)
Gram positive
Enterococcus faecalis 10
Listeria monocytogenes 20
MSSA 5
MRSA 5
Gram negative
Eschericia coli 10
Eschericia coli ESBL 10
Klebsiella pneumoniae 20
Klebsiella pneumoniae ESBL 20
Morganella morganii >20
Pseudomonas aeruginosa >20
Proteus mirabilis 20
Candida albicans >20
The antioxidant activity was expressed as EC50 values, where lower values corre-
spond to higher antioxidant potential. Trolox (positive control) EC50 values: 41 mg/
mL (reducing power), 42 mg/mL (DPPH scavenging activity). Anti-inﬂammatory
activity is expressed as EC50 values corresponding to 50% of inhibition of the NO
production in comparison with the negative control (100% of NO production).
Dexamethasone (positive control) EC50 values: 16 mg/mL. Anti-tyrosinase activity is
expressed as EC50 values corresponding to 50% of inhibition of tyrosinase. Ascorbic
acid (positive control) EC50 values: 31 mg/mL. Cytotoxicity results are expressed as
GI50 values corresponding to the sample concentration responsible for 50% of
growth inhibition in human tumour cell lines or in liver primary culture PLP2.
Ellipticine (positive control) GI50 values: 1.21 mg/mL (MCF-7), 1.03 mg/mL (NCI-
H460), 0.91 mg/mL (HeLa), 1.10 mg/mL (HepG2) and 2.29 (PLP2). Minimum Inhibitory
concentration-MIC, MRSA- Methicillin-resistant Staphylococcus aureus; MSSA
methicillin susceptible S. aureus; ESBL-spectrum extended producer of b e
lactamase.
Table 4
Physico-chemical and bioactive properties of G. lucidum cosmeceutical formulation.
G. lucidum cosmeceutical formulation
Physico-chemical properties
Colour
L* 70.3 ± 0.7
a* 12.1 ± 0.5
b* 32.9 ± 0.9
pH 4.61 ± 0.03
Bioactive properties
Antioxidant activity (EC50 values, mg/mL)
DPPH scavenging activity 34 ± 1
Reducing power 13.60 ± 0.09
Antityrosinase activity (EC50 values, mg/mL)
L-DOPA assay 23.80 ± 0.03
Antimicrobial activity (MIC, mg/mL)
Enterococcus faecalis 200
Listeria monocytogenes 400
MSSA 100
MRSA 100
Eschericia coli 200
Eschericia coli ESBL 200
Klebsiella pneumoniae 400
Klebsiella pneumoniae ESBL 400
Morganella morganii >400
Pseudomonas aeruginosa >400
Proteus mirabilis 400
Candida albicans >400
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bacteria. The antimicrobial activity of G. lucidum has been widely
studied, and according to the review conducted by Alves et al.
(2013), extracts of G. lucidum revealed antimicrobial activity
against B. subtilis, S. aureus, E. coli, K. pneumoniae, P. aeruginosa, S.
typhi, and S. Typhimurium. The phenolic acids present in this
mushroom have been identiﬁed as themost important contributors
to this activity (Heleno et al., 2013). These authors went further to
evaluate the antimicrobial activity of these phenolic acids de-
rivatives (glucuronated and methylated) to conﬁrm if they reveal
activity in their in vivo form after undergoing metabolism. In the
review conducted by Ferreira et al. (2015) the polysaccharide
fractions have also been described to contribute signiﬁcantly to the
antimicrobial activity of this mushroom. Thus, further studies need
to be conducted with this extract by testing other bacterial and
fungal strains to conﬁrm its broad spectrum of antimicrobial
activity.
3.3. G. lucidum ethanolic extracts in cosmeceutical formulations
The term “cosmeceutical” was ﬁrst introduced by AlbertKligman, MD, Ph.D in 1984 at the National Scientiﬁc Meeting of the
Society of Cosmetic Chemists (Kligman, 2006). This term is an
interphase between cosmetics and pharmaceuticals since they are
products formulated with bioactive ingredients, topically applied
on the skin to produce a medical drug-like beneﬁt, while also
improving skin structure and function (Taoﬁq et al., 2016a). The use
of bioactive products such as vitamins, peptides, phenolic com-
pounds, polyhydroxy acids, obtained from plant, mushroom and
other natural matrices, as cosmeceutical ingredients, have received
increased attention because of their multifunctional beneﬁts on
skin (e.g. antioxidant, antityrosinase, anti-hyaluronidase, anti-
collagenase, anti-elastase, photoprotective, antimicrobial and anti-
inﬂammatory).
In the present study, the results of antioxidant, antimicrobial
and antityrosinase activities for the produced cosmeceutical
formulation are presented in Table 4. The cosmeceutical formula-
tions maintain the bioactivities exhibited by the extract. This
achievement is quite interesting regarding the concern of cosmetic
industry in reducing the presence of synthetic ingredients, and its
gradual replacement by natural counterparts, due to the increased
awareness on the negative effects reported for some artiﬁcial
antimicrobial agents. In fact, natural bioactive compounds with a
broad spectrum of antimicrobial properties are being slowly
introduced in this industrial ﬁeld, also justiﬁed by their multi-
functional properties (Kerdudo et al., 2016). The formulations
incorporated with G. lucidum extract were able to signiﬁcantly
inhibit the growth of MSSA and MRSA by presenting a low mini-
mum inhibitory concentration. Also, this work demonstrates that
extracts of G. lucidum have interesting biological properties that can
be exploited in the design of cosmeceutical formulations either as
tyrosinase inhibitors, anti-inﬂammatory agents or as preservatives
to prolong the shelf life of the formulated product. The compounds
earlier identiﬁed in the ethanolic extract were monitored by HPLC-
DAD-ESI/MS and found to be present in the produced cosmeceut-
ical formulation.
The relevance of G. lucidum properties is evident from the
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formulated from their extracts, either alone or in combination with
other natural ingredients. Examples include Body Repair Lotion (G.
lucidum extract andmedicinal plant), Dr. AndrewWeil for Origins™
Mega-Mushroom Skin Relief Face Mask (G. lucidum, C. sinensis and
medicinal plants) and Menard Embellir Refresh Massage cream (G.
lucidum and G. sinense). These products have all been used to
suppress the severity of hyperpigmentation, to brighten skin
appearance and prevent aging effects, and to protect skin against
UV radiation (Taoﬁq et al., 2016a). Even though the individual
contribution of their constituents needs to be established, there are
reports claiming that terpenes such as monoterpenes and sesqui-
terpenes have potential to enhance compound penetration across
the skin by decreasing skin barrier resistance of the stratum cor-
neum (Lane, 2013). Thus, the content of terpenoids determined for
G. lucidum can play an important role by enhancing the topical
availability of other constituents in cosmeceutical formulations.
In today's cosmetic market a wide variety of choices is offered to
consumers, being colour attributes an important characteristic for
their acceptance. Hence, companies have paid lots of attention in
managing colour display during product design and formulation. In
the present work, the colour attributes of the produced cosme-
ceutical formulation showed a light-yellow colouration. The rate of
dermal absorption of topical formulations such as lotions and
creams are often inﬂuenced by the pH of the product. The pH of
skin external surface is around 5.5, and at this condition, the skin
micro-ﬂora, barrier homeostasis and stratum corneum are main-
tained (Ali and Yosipovitch, 2013; Martínez-Pla et al., 2004). Most
reports have suggested that a pH between 4 and 6.5 can be
considered as adequate for cosmetic formulations since most
pathogenic bacteria (e.g. S. aureus), thrive best at neutral pH levels
(Ali and Yosipovitch, 2013). In the present work, the cosmeceutical
formulation presented a pH 4.6, which is considered within the
favourable pH range.
4. Conclusion
Overall, beyond the important nutritional composition of G.
lucidum that can be essential for nutraceutical's development, its
ethanolic extract showed several bioactive properties ideal to be
exploited in the development of cosmeceutical formulations. The
presence of different bioactive molecules in the classes of phenolic
compounds, terpenes, specially triterpenes can be correlated with
the exhibited bioactivity. Even so, further studies needed to be
conducted in order to better understand the mechanism of action
of G. lucidummetabolites and identify the most important subtypes
behind each observed bioactivity. Furthermore, issues related with
stability, skin permeation, efﬁcacy and topical bioavailability are
major concerns that need to be addressed. Hence, conducting skin
permeation studies using in vitro skin models, the use of nano-
technology techniques as bioactive compound delivery system and
evaluating the stability of the formulations prepared at different
storage time and temperature will further conﬁrm the potential of
G. lucidum extracts as topical ingredients. Also, further in vivo and
clinical studies are necessary in order to develop and validate novel
nutraceuticals, cosmeceuticals and pharmacological formulations.
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